Androgen Receptor, Implications for Health and Wellbeing: Natural History Study of Individuals With Androgen Insensitivity

Conditions

• Androgen Insensitivity Syndrome
• Metabolic Parameters in AIS, CAIS, PAIS and MAIS
• Sexual Function AIS, CAIS, PAIS and MAIS
• Tumor Formation in AIS, CAIS, PAIS and MAIS

Eligibility Criteria

Sex

ALL

Age

1 Year - 99 Years

Healthy Volunteers

Accepted

Study Details

Background: Androgen effects in humans are usually (but not always) mediated by the androgen receptor which is coded for by the androgen receptor gene (AR gene). Androgen Insensitivity Syndrome (AIS) is a rare condition in which the body cannot sense the male hormones in the blood or tissue. Both women and men can be affected by AIS. Researchers want to learn more about the health of people with AIS over time. With a natural history study in individuals with AIS, data and tests may provide information regarding health risks (including the risks and benefits of gonadectomy and best ways to monitor for tumor) and optimal management of individuals with AIS as well as elucidate the role of the androgen receptor in human health. This study does not involve any interventions and we can provide clinical care while collecting data. Objective: The objective of this natural history study is to describe and define a comprehensive phenotype (characteristic) of patients with AIS based on confirmed androgen receptor (AR) gene difference. We will evaluate hormones, bone density and markers, cardiovascular and metabolic parameters, as well as quality of life and tumor formation risk and evaluation. The purpose is to obtain a better understanding of the overall health issues that people with AIS may have through the study procedures listed. Eligibility: People ages 0-99 with AIS and their adult relatives Design: Participants will go through a series of study procedures for data and specimen collection. This will be done to understand how AIS affects individuals since the androgen receptor is found in many tissues in the body including skin, bone, muscle, and the neurologic, immune and metabolic systems. All tests will be performed by skilled and trained study professionals. Participants will be screened with: Medical history Physical exam Medical record review Lab tests. Participants will have physical exams. Their body measurements will be taken. They will have blood and urine tests. They will have electrocardiograms to check heart health. They may complete questionnaires. They may have an Oral Glucose Tolerance Test. Participants may have x-rays and HRpQCT scans taken of the hand, wrist, and other bones. Participants will have body scans to measure bone thickness. Participants will have magnetic resonance imaging (MRI) or sonogram of the pelvis. For MRI, they may get a contrast agent via intravenous (IV) catheter. Adult participants may have the following: MR elastography. It uses MRI and low-frequency vibrations to map stiffness of body tissues. MR spectroscopy. It uses MRI to take pictures of chemicals in the liver and body fat. Cardiac computed tomography scan. It uses x-rays to make pictures of the heart. Participants may get a contrast agent via IV. Optional genital exam. Participants will have visits every 1-2 years. Participation lasts indefinitely. Adult relatives will also be invited to participate but will have only 1 visit. It will include some of the above tests.

Key Dates

Start date

Apr 29, 2021

Status verified

May 2026

Primary completion

Feb 1, 2040

Completion

Feb 1, 2040

Study Design

Enrollment

650 participants (estimated)

Arms

• Arm: Female subjects relatives who are carriers of the AR gene difference
  We will enroll 50 female subjects relatives AIS subjects who are carriers of the AR gene difference
• Arm: Female subjects relatives who are not carriers of the AR gene
  We will enroll 50 female subjects relatives of AIS subjects who are not carriers of the AR gene.
• Arm: Healthy male subjects relatives
  We will enroll 50 healthy male subjects of AIS relative subjects
• Arm: Subjects with androgen receptor mutations
  500 Subjects with confirmed androgen receptor mutations

Primary Outcome Measure

To define and describe a comprehensive phenotype in 500 patients with androgen insensitivity [ Time Frame: End of study ]

Central Contacts

• Veronica Gomez-Lobo, M.D.
  (301) 435-7567
  [email protected]

Locations (1)

Find similar trials in Bethesda, MD